Citeline Podcasts

On this week's podcast, the "Gray Sheet" team discussed the latest in user fee negotiations, cybersecurity, sterile devices and interoperability, as well as a focus on Zika virus diagnostics, HeartWare International's abandoned acquisition, a Boston Scientific legal update and more.

On this week's podcast, the "Gray Sheet" team discussed the latest in user fee negotiations, cybersecurity, sterile devices and interoperability, as well as a focus on Zika virus diagnostics, HeartWare International's abandoned acquisition, a Boston Scientific legal update and more.

On this week's podcast, the "Gray Sheet" team discussed the latest in user fee negotiations, cybersecurity, sterile devices and interoperability, as well as a focus on Zika virus diagnostics, HeartWare International's abandoned acquisition, a Boston Scientific legal update and more.

On this week's podcast, the "Gray Sheet" team discussed the latest in user fee negotiations, cybersecurity, sterile devices and interoperability, as well as a focus on Zika virus diagnostics, HeartWare International's abandoned acquisition, a Boston Scientific legal update and more.

On this week's podcast, "Gray Sheet" journalists spoke about 2015 warning letter trends, Senate plans for device reforms, legal updates and FDA's latest device cybersecurity efforts.

On this week's podcast, "Gray Sheet" journalists spoke about 2015 warning letter trends, Senate plans for device reforms, legal updates and FDA's latest device cybersecurity efforts.

On this week's podcast, "Gray Sheet" journalists spoke about 2015 warning letter trends, Senate plans for device reforms, legal updates and FDA's latest device cybersecurity efforts.

On this week's podcast, "Gray Sheet" journalists spoke about 2015 warning letter trends, Senate plans for device reforms, legal updates and FDA's latest device cybersecurity efforts.

In this "Gray Sheet" podcast interview, industry insider Steve Niedelman looks in his proverbial crystal ball and tells what quality and regulatory professionals should keep a sharp eye on this year, including FDA's inspectional program alignment, quality metrics, warning letters, third-party supplier programs and risk management.

In this "Gray Sheet" podcast interview, industry insider Steve Niedelman looks in his proverbial crystal ball and tells what quality and regulatory professionals should keep a sharp eye on this year, including FDA's inspectional program alignment, quality metrics, warning letters, third-party supplier programs and risk management.